Chow James C H, Cheung Ka-Man, Cheung Gavin T C, Tam Anthony H P, Lui Jeffrey C F, Lee Francis K H, Au Kwok-Hung, Ng Wai-Tong, Lee Anne W M, Yiu Harry H Y
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Clin Transl Radiat Oncol. 2022 Jan 24;33:83-92. doi: 10.1016/j.ctro.2022.01.001. eCollection 2022 Mar.
This systematic review aims to identify radiation dose-volume predictors of primary hypothyroidism after radiotherapy in patients with head and neck cancer (HNC).
We performed a systematic literature search of Medline, EMBASE and Web of Science from database inception to July 1, 2021 for articles that discuss radiation dose-volume predictors of post-radiation primary hypothyroidism in patients with HNC. Data on the incidence, clinical risk factors and radiation dose-volume parameters were extracted. A meta-analysis was performed using the random-effects model to estimate the pooled odds ratio (OR) of thyroid volume as a predictor of the risk of post-radiation hypothyroidism, adjusted for thyroid radiation dosimetry.
Our search identified 29 observational studies involving 4,530 patients. With median follow-up durations ranging from 1.0 to 5.3 years, the average crude incidence of post-radiation primary hypothyroidism was 41.4 % (range, 10 %-57 %). Multiple radiation dose-volume parameters were associated with post-radiation primary hypothyroidism, including the thyroid mean dose (Dmean), minimum dose, V25, V30, V35, V45, V50, V30-60, VS45 and VS60. Thyroid Dmean and V50 were the most frequently proposed dosimetric predictors. The pooled adjusted OR of thyroid volume on the risk of post-radiation primary hypothyroidism was 0.89 (95 % confidence interval, 0.85-0.93; p < 0.001) per 1 cc increment.
Post-radiation primary hypothyroidism is a common late complication after radiotherapy for HNC. Minimizing inadvertent exposure of the thyroid gland to radiation is crucial to prevent this late complication. Radiation dose-volume constraints individualized for thyroid volume should be considered in HNC radiotherapy planning.
本系统评价旨在确定头颈部癌(HNC)患者放疗后原发性甲状腺功能减退的辐射剂量-体积预测因素。
我们对Medline、EMBASE和Web of Science进行了系统的文献检索,检索时间从数据库建立至2021年7月1日,以查找讨论HNC患者放疗后原发性甲状腺功能减退的辐射剂量-体积预测因素的文章。提取了关于发病率、临床风险因素和辐射剂量-体积参数的数据。采用随机效应模型进行荟萃分析,以估计甲状腺体积作为放疗后甲状腺功能减退风险预测因素的合并比值比(OR),并根据甲状腺辐射剂量测定法进行调整。
我们的检索共识别出29项观察性研究,涉及4530例患者。中位随访时间为1.0至5.3年,放疗后原发性甲状腺功能减退的平均粗发病率为41.4%(范围为10% - 57%)。多个辐射剂量-体积参数与放疗后原发性甲状腺功能减退相关,包括甲状腺平均剂量(Dmean)、最小剂量、V25、V30、V35、V45、V50、V30 - 60、VS45和VS60。甲状腺Dmean和V50是最常被提出的剂量学预测因素。甲状腺体积每增加1 cc,放疗后原发性甲状腺功能减退风险的合并调整OR为0.89(95%置信区间,0.85 - 0.93;p < 0.001)。
放疗后原发性甲状腺功能减退是HNC放疗后常见的晚期并发症。尽量减少甲状腺意外受到辐射对于预防这种晚期并发症至关重要。在HNC放疗计划中应考虑根据甲状腺体积个体化的辐射剂量-体积限制。